



Perspectives on DoReMi from an External Advisory Board Member

In a visionary move, the High Level Expert Group (HLEG) proposed a bold yet comprehensive strategy for low dose radiation health research in Europe. As a result the MELODI platform was created to promote and coordinate low dose research at an international level. In turn, the European Network of Excellence launched DoReMi as an operational tool to develop and foster low dose research.

I consider it an honor and a privilege to be invited to participate and interact with DoReMi as a member of the External Advisory Board (EAB). As an outsider, not funded by the program I can look at the DoReMi program, administratively in terms of its management and coordination, as well as scientifically, monitoring productivity and progress. The role of the EAB is to provide objective and constructive advice, independent of the either the funding organization or the scientists involved. It is impressive how DoReMi has evolved and matured into an interactive and productive research program. This reflects favorably on the management, the Work Package leaders as well as the scientists in the laboratories doing the work.

It also reflects well on the vision of HLEG. Evaluating low dose radiation effects is not a simple task, and the results will never be black or white. HLEG's long-term program ensures stability in the field, and gives young investigators the opportunity for outstanding training, and encourages them to stay in the field. As the radiation community ages the influx of bright, well trained young investigators is viewed by the EAB as a major contribution to science in Europe. The EAB acknowledges that this could not be achieved without solid management and strong leadership (WP1); an integrated and

well-structured path forward (WP2); excellent education and training (WP3); and an infrastructure to allow this to happen (WP4).

However, it is the science that is the key. As an EAB member it is extremely rewarding to attend the periodic meeting. Critical issues are being addressed: individual susceptibilities and sensitivity (WP6); the shape of the dose response curve (WP5) and non-cancer effects (WP7) at low doses and dose rates are very relevant to society. The senior leadership is made up of outstanding individuals who will continue to disseminate the results of DoReMi activities, and ensure DoReMi remains aware of future societal and scientific developments.

The role of the EAB is to help DoReMi continue to achieve these lofty goals. It is to ADVISE by providing an independent perspective. It DOES NOT demand changes be made. The EAB can also evaluate progress and recommend to the MB future directions to achieve the goals identified by HLEG in order to help maintain the high standard of research achieved to date. The EAB looks forward to continued interactions and more excellent science in the future.

Prof. William F. Morgan

Chair of the EAB

Pacific Northwest National Laboratory, USA



OPERRA – Open Project for European Radiation Research Area

The OPERRA project has started in June 2013 and it aims to build up a coordination structure that has the legal and logistical capacity to administer future calls for research proposals in radiation protection on behalf of the European Commission.

Among OPERRA's initiatives are the set-up of a sustainable organisation to manage radiation protection research in Europe; the involvement of key partners in radiation protection as well as national and international funding agencies; and the enrollment of universities and academic partners, notably from new EU Member States, major stakeholders and authorities as well as other technical platforms inside and outside Euratom. For further information, please read the OPERRA [description](#) and see the [presentation](#).

DoReMi Training courses

Two training courses will be organised in year 2013:

- 4–22 November: Training course in Radiation Epidemiology and Dosimetry by HMGU in Munich, Germany. More information available [here](#).
- 9–20 December: Inter-individual responses to low dose ionizing radiation: from damage formation to biomarkers by IC and CEA in Paris, France. More information available [here](#).

For the courses scheduled in 2014, please visit [the course calendar](#).

DoReMi has passed its mid-term

DoReMi project started in January 2010 and is scheduled to end in December 2015, so it has already passed its mid-term. Summary of the work achieved after DoReMi's second 18 months reporting period is available [here](#).

Subscription info

DoReMi Newsletters are published roughly every three months. They are sent to subscribers and published on DoReMi website. If you wish to receive the DoReMi Newsletters directly by email, please subscribe by sending a message to doremi@stuk.fi.

DoReMi and related events

Future events

- **DoReMi Workshop Low dose radiation effects on the immune system: current knowledge and future research needs** will be organised on 5–7 November 2013 in Budapest, Hungary. More information available [here](#).

Past events

- **DoReMi Radiation Quality Workshop** was organised on 9–10 July 2013 in Brussels, Belgium. The materials of the workshop are available [here](#).

Highlights and interesting documents available

Three new peer-reviewed publications are available in the [DoReMi Scientific Information Centre](#):

- "Live cell detection of chromosome 2 deletion and Sfp1/PU1 loss in radiation-induced mouse acute myeloid leukaemia" by Olme CH et al., published in *Leukemia Research*.
- "Developmental and oncogenic radiation effects on neural stem cells and their differentiating progeny in mouse cerebellum" by Tanori M et al., published in *Stem Cells*.
- "The PI3K/Akt/mTOR Pathway Is Implicated in the Premature Senescence of Primary Human Endothelial Cells Exposed to Chronic Radiation" by Yentrapalli R et al., published in *PLOS One*.

